Afya (NASDAQ:AFYA - Get Free Report) will likely be releasing its earnings data before the market opens on Thursday, March 13th. Analysts expect Afya to post earnings of $0.36 per share and revenue of $848.25 million for the quarter. Persons interested in participating in the company's earnings conference call can do so using this link.
Afya Stock Up 2.9 %
NASDAQ:AFYA traded up $0.49 during mid-day trading on Friday, hitting $17.13. The stock had a trading volume of 76,422 shares, compared to its average volume of 97,610. The stock has a 50-day simple moving average of $16.32 and a two-hundred day simple moving average of $16.49. The company has a market capitalization of $1.61 billion, a PE ratio of 13.81, a PEG ratio of 0.29 and a beta of 0.82. Afya has a twelve month low of $14.52 and a twelve month high of $22.24. The company has a current ratio of 1.60, a quick ratio of 1.60 and a debt-to-equity ratio of 0.51.
Analyst Upgrades and Downgrades
Several analysts recently weighed in on AFYA shares. JPMorgan Chase & Co. reduced their target price on shares of Afya from $25.00 to $20.50 and set a "neutral" rating on the stock in a report on Friday, January 17th. The Goldman Sachs Group started coverage on shares of Afya in a report on Tuesday, December 3rd. They issued a "sell" rating and a $16.00 target price on the stock. Finally, Citigroup reaffirmed a "sell" rating and issued a $15.00 target price (down previously from $18.00) on shares of Afya in a report on Friday, January 31st. Two research analysts have rated the stock with a sell rating and three have assigned a hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $18.00.
Read Our Latest Research Report on Afya
Afya Company Profile
(
Get Free Report)
Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. The company operates through three segments: Undergrad, Continuing Education, and Digital Services. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools.
Further Reading
Before you consider Afya, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Afya wasn't on the list.
While Afya currently has a Strong Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
